Format

Send to

Choose Destination
Int J Antimicrob Agents. 2018 Apr;51(4):571-577. doi: 10.1016/j.ijantimicag.2017.11.008. Epub 2017 Nov 24.

Dalbavancin in the treatment of different gram-positive infections: a real-life experience.

Author information

1
Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain; Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain; CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
2
Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain. Electronic address: maricela.valerio@hotmail.com.
3
Department of Infectious Diseases, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.
4
Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
5
Infectious Diseases Service, Hospital Universitario Virgen de las Nieves, Granada.
6
Department of Infectious Diseases, Hospital Regional Universitario de Málaga, Málaga, Spain.
7
Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain; Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain; CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. Electronic address: pmunoz@hggm.es.
8
Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain; Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
9
Mar Sánchez-Somolinos, Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid.
10
Infectious Diseases Unit, Complejo Hospitalario de Jaén, Jaén.
11
Department of Internal Medicine, Hospital Universitario Doctor Peset, Valencia.
12
Department of Internal Medicine, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid.
13
Infectious Diseases Unit, Hospital General Universitario Reina Sofia, Murcia.
14
Department of Clinical Microbiology. Hospital Clínico San Carlos, Madrid.
15
Department of Infectious Diseases, Complejo Hospitalario Universitario A Coruña, La Coruña.
16
Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Madrid.
17
Infectious Diseases Unit, Complejo Hospitalario Torrecárdenas, Almería.
18
Department of Infectious Diseases, Hospital del Mar, Barcelona.
19
Internal medicine department, Ruber Juan Bravo Hospital, Madrid.
20
Department of Internal Medicine, Hospital Universitario Fundación De Alcorcón, Madrid.
21
Department of Internal Medicine, Hospital Universitari de Sant Joan de Déu, Barcelona.
22
Clinical Unit of Infectious Diseases, Hospital Universitario Virgen del Rocío, Sevilla.
23
Infectious Diseases Unit, Hospital Universitario de Sant Joan d'Alacant, Alicante.
24
Department of Internal Medicine, Hospital POVISA, Vigo.
25
Department of Internal Medicine, Hospital de Poniente, Almería.
26
Department of Internal Medicine, Hospital Universitario Infanta Sofia, Madrid.
27
Infectious Diseases Unit, Hospital General Universitario De Elche, Alicante.
28
Infectious Diseases Unit, Department of Internal Medicine, Hospital Clínic Universitari València, Valencia.
29
Infectious Diseases and Clinical Microbiology Unit, Hospital Universitario La Paz, Madrid.
30
Department of Infectious Diseases, Hospital De Vall'd Hebron, Barcelona.
31
Department of Internal Medicine, Hospital Universitario de Getafe, Madrid.
32
Infectious Diseases Unit, Hospital Universitario 12 de Octubre, Madrid.
33
Department of Internal Medicine, Hospital Universitario de La Princesa, Madrid.
34
Department of Internal Medicine, Complejo Hospitalario de Toledo, Toledo.
35
Department of Infectious Diseases, Hospital Regional Universitario de Málaga, Málaga.
36
Infectious Diseases Division, Hospital del Mar, Barcelona.

Abstract

Dalbavancin is a lipoglycopeptide with a very prolonged half-life enabling treatment with a single intravenous administration that has been approved to treat complicated skin and soft-tissue infections. Information on the efficacy and safety of dalbavancin in other situations is very scarce. This retrospective study included adult patients who received at least one dose of dalbavancin between 2016 and 2017 in 29 institutions in Spain. The primary objective was to report the use of dalbavancin in clinical practice, including its efficacy and tolerability. The potential impact of dalbavancin on reducing the length of hospital stay and hospital costs was also evaluated. A total of 69 patients received dalbavancin during the study period (58.0% male; median age 63.5 years). Dalbavancin was used to treat prosthetic joint infection (29.0%), acute bacterial skin and skin-structure infection (21.7%), osteomyelitis (17.4%) and catheter-related bacteraemia (11.6%). These infections were mainly caused by Staphylococcus aureus (27 isolates), coagulase-negative staphylococci (24 isolates) and Enterococcus spp. (11 isolates). All but two patients received previous antibiotics for a median of 18 days. Dalbavancin was administered for a median of 21 days (range 7-168 days), and concomitant antimicrobial therapy was prescribed to 25 patients (36.2%). The overall clinical success rate of dalbavancin was 84.1%. Adverse events, mainly mild in intensity, were reported in nine patients. Overall, dalbavancin was estimated to reduce hospitalisation by 1160 days, with an estimated overall cost reduction of €211 481 (€3064 per patient). Dalbavancin appears to be an effective therapy for many serious Gram-positive infections.

KEYWORDS:

Dalbavancin; Gram-positive infection; Skin and soft-tissue infection

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center